Pharmaceutical and biological industry performance slightly weaker week cumulatively up 0.97%

the two markets rebounded last week, the pharmaceutical and biological sector performance slightly weak, the weekly cumulative rise of 0.97 percent, the performance lags behind the broader market.
analysts said that since December 2018, the pharmaceutical industry policy, including the "4 plus 7 cities" drug centralized procurement, the National Health and Health Commission called for the development of a national list of auxiliary drugs, the State Health Insurance Administration to organize drGs national pilot declaration work, the market for the pharmaceutical industry Policy concerns were released in the current round of adjustment, the current absolute valuation of the pharmaceutical sector compared with the mid-decade 37.3 times (the lowest value of 19.5 times in November 2008) is at an all-time low, the pharmaceutical sector's cost-effective advantage is expected to lead to a rebound in the overall business climate of the sector. In the short term, the market remains concerned about the possible impact of follow-up policies on volume procurement, particularly with regard to the linkage of winning bid prices, and it is recommended to focus on sub-sectors with less policy impact and high performance certainty.
Galaxy Securities said that overall, with volume procurement will play a vital fulcum role in the three-doctor linkage, will also help the reform of the health care system on the right track to accelerate, is conducive to the long-term healthy development of the industry, so the importance of the successful implementation of the "4 plus 7" is self-evident. It is recommended to pay attention to the supplementary documentation of the provinces, including the standard of payment for medical insurance, the repayment mechanism, and the clinical use tracking of the selected varieties. (China Securities News, China Securities Exchange Network)